ArticleFrontiers in medicine2026
Development and validation of a novel nomogram for predicting long-term survival in patients with decompensated cirrhosis undergoing TIPS.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and aims: Transjugular intrahepatic portosystemic shunt (TIPS) is a critical intervention for complications of decompensated cirrhosis. However, traditional scoring systems like MELD and CTP have limitations in predicting long-term post-TIPS survival, particularly in populations with viral hepatitis. This study aimed to develop and validate a novel nomogram to predict 1-, 3-, and 5-year overall survival (OS) in patients with decompensated cirrhosis undergoing TIPS. Methods: We conducted a single-center retrospective study enrolling 409 patients with decompensated cirrhosis who received their first TIPS treatment between January 2017 and December 2023. Patients were randomly assigned to a training cohort ( Results: Six independent predictors were identified: age, serum ammonia, total cholesterol, total bilirubin, albumin, and creatinine. The nomogram demonstrated superior discrimination, the areas under the ROC curve (AUCs) for 1-, 3-, and 5-year OS were 0.79, 0.82, and 0.84 in the training cohort, and 0.81, 0.75, and 0.80 in the validation cohort, respectively. Calibration curves showed excellent agreement between predicted and observed survival, and DCA indicated significant clinical net benefit. Conclusion: We developed a robust nomogram integrating hepatic, renal, and metabolic indicators to predict long-term survival in post-TIPS patients. This model offers superior accuracy compared to traditional scoring systems, facilitating better risk stratification and individualized clinical decision-making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.